Siegfried, a global Contract Development and Manufacturing Organization (CDMO) listed on the SIX Swiss Exchange (SIX: SFZN), has appointed Eduardo Montanha as Chief Operating Officer and member of the Executive Committee, effective September 1, 2026. The appointment follows the company's previously announced decision to consolidate the Chief Operating Officer roles for Drug Substances and Drug Products into a single position, a move that supports Siegfried's strategy to offer integrated end-to-end solutions across the pharmaceutical value chain.
Eduardo Montanha brings more than 20 years of international leadership experience in pharmaceutical and biopharmaceutical manufacturing. Most recently, he served as Executive Vice President, Head of Global Technical Operations & Quality at Fresenius Kabi, where he led an integrated global network of around 30 manufacturing sites across multiple regions. Earlier in his career, he held senior leadership positions at Takeda, Sandoz, Hexal, and Hoechst/Aventis, covering technical operations, quality, supply, and large-scale manufacturing networks. With his strong track record in integrated operations, Montanha will focus on further strengthening supply performance, operational efficiency, and reliability across Siegfried's global network.
Marcel Imwinkelried, Chief Executive Officer of Siegfried, stated: "I am very pleased to welcome Eduardo to Siegfried. He brings outstanding global operations and quality leadership experience and will play an important role in further enhancing supply performance, operational efficiency and reliability for our customers."
Eduardo Montanha holds a bachelor's degree in chemical engineering, a postgraduate qualification in Industrial Automation, and an MBA in Project Management. He brings extensive international leadership experience, having lived and worked across Europe and Latin America. The appointment underscores Siegfried's commitment to operational excellence as it continues to expand its capabilities in manufacturing pharmaceutical active pharmaceutical ingredients (APIs) and drug products such as tablets, capsules, sterile vials, ampoules, cartridges, and ointments, as well as providing development services.
This structural change is expected to enhance Siegfried's ability to deliver integrated solutions, improving supply chain efficiency and customer service. The company's global network includes 16 sites in Switzerland, Germany, Spain, France, Malta, the USA, Australia, and China, and in 2025 it achieved sales of CHF 1,327.8 million with over 3,800 employees. The appointment of Montanha is a strategic move to streamline operations and better serve the pharmaceutical industry's growing demand for end-to-end manufacturing services.
For more information, visit the original release on NewMediaWire.
